Fresenius Medical Care Corporation (NYSE:FMS) Position Boosted by Ferguson Wellman Capital Management Inc.

Ferguson Wellman Capital Management Inc. increased its stake in shares of Fresenius Medical Care Corporation (NYSE:FMS) by 0.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 141,286 shares of the company’s stock after buying an additional 800 shares during the period. Ferguson Wellman Capital Management Inc.’s holdings in Fresenius Medical Care Corporation were worth $6,828,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in FMS. Harding Loevner LP increased its stake in shares of Fresenius Medical Care Corporation by 7.1% in the first quarter. Harding Loevner LP now owns 3,528,960 shares of the company’s stock valued at $148,675,000 after buying an additional 233,347 shares during the last quarter. Cambiar Investors LLC increased its stake in Fresenius Medical Care Corporation by 8.1% in the first quarter. Cambiar Investors LLC now owns 2,516,416 shares of the company’s stock valued at $106,017,000 after buying an additional 188,019 shares in the last quarter. Bank of America Corp DE increased its stake in Fresenius Medical Care Corporation by 12.1% in the first quarter. Bank of America Corp DE now owns 1,493,411 shares of the company’s stock valued at $62,917,000 after buying an additional 161,262 shares in the last quarter. US Bancorp DE increased its stake in Fresenius Medical Care Corporation by 10.4% in the second quarter. US Bancorp DE now owns 427,021 shares of the company’s stock valued at $20,637,000 after buying an additional 40,121 shares in the last quarter. Finally, Parametric Portfolio Associates LLC increased its stake in Fresenius Medical Care Corporation by 21.4% in the first quarter. Parametric Portfolio Associates LLC now owns 369,566 shares of the company’s stock valued at $15,570,000 after buying an additional 65,196 shares in the last quarter. Institutional investors and hedge funds own 2.81% of the company’s stock.

Shares of Fresenius Medical Care Corporation (NYSE FMS) opened at 46.38 on Friday. The company has a market capitalization of $28.46 billion, a P/E ratio of 20.25 and a beta of 0.47. The stock has a 50 day moving average price of $47.31 and a 200-day moving average price of $44.97. Fresenius Medical Care Corporation has a one year low of $38.05 and a one year high of $50.22.

Fresenius Medical Care Corporation (NYSE:FMS) last issued its earnings results on Tuesday, August 1st. The company reported $0.48 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.53 by $0.05. Fresenius Medical Care Corporation had a return on equity of 11.57% and a net margin of 7.06%. The company had revenue of $4.47 billion during the quarter, compared to analyst estimates of $5.20 billion. During the same period in the previous year, the company posted $0.96 earnings per share. The company’s quarterly revenue was up 11.1% on a year-over-year basis. Equities research analysts predict that Fresenius Medical Care Corporation will post $2.33 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Fresenius Medical Care Corporation (NYSE:FMS) Position Boosted by Ferguson Wellman Capital Management Inc.” was originally published by BNB Daily and is owned by of BNB Daily. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.baseball-news-blog.com/2017/08/19/fresenius-medical-care-corporation-nysefms-position-raised-by-ferguson-wellman-capital-management-inc-updated-updated.html.

Several equities research analysts have issued reports on the company. UBS AG restated a “sell” rating on shares of Fresenius Medical Care Corporation in a report on Tuesday, July 4th. Zacks Investment Research downgraded Fresenius Medical Care Corporation from a “strong-buy” rating to a “hold” rating in a report on Wednesday. BidaskClub downgraded Fresenius Medical Care Corporation from a “strong-buy” rating to a “buy” rating in a report on Monday, July 24th. Nord/LB restated a “buy” rating on shares of Fresenius Medical Care Corporation in a report on Wednesday, June 28th. Finally, Royal Bank Of Canada restated a “neutral” rating and set a price objective on shares of Fresenius Medical Care Corporation in a report on Tuesday, August 8th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and seven have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $48.67.

Fresenius Medical Care Corporation Company Profile

Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.

Institutional Ownership by Quarter for Fresenius Medical Care Corporation (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply